LGND - LIGAND PHARMACEUTICALS INC
208.95
4.710 2.254%
Share volume: 189,218
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$204.24
4.71
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-08-2024 | 08-07-2024 | 11-08-2024 | 02-28-2025 | 05-09-2025 | 08-08-2025 | 11-07-2025 | |
| Assets | ||||||||
| Total Assets | 913.869 M | 866.405 M | 954.866 M | 941.774 M | 905.435 M | 948.604 M | 1.477 B | |
| Current Assets | 368.913 M | 312.259 M | 309.388 M | 331.559 M | 309.316 M | 352.945 M | 753.920 M | |
| Inventories | 21.337 M | 18.672 M | 16.740 M | 14.114 M | 14.614 M | 15.489 M | 11.900 M | |
| Other Current Assets | 7.311 M | 27.263 M | 30.874 M | 16.897 M | 42.970 M | 50.320 M | 19.402 M | |
| Short Term Investments | 260.500 M | 208.793 M | 156.024 M | 183.858 M | 160.912 M | 177.351 M | 525.146 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 50.093 M | 18.139 M | 63.619 M | 72.307 M | 47.989 M | 67.669 M | 139.376 M | |
| Total Non-current Assets | 46.969 M | 13.178 M | 13.153 M | 10.908 M | 10.908 M | 10.908 M | 148.721 M | |
| Property Plant Equipment | 15.135 M | 14.970 M | 15.094 M | 15.133 M | 3.623 M | 3.632 M | 3.466 M | |
| Other Assets | 529.821 M | 539.176 M | 630.384 M | 595.082 M | 592.496 M | 592.027 M | 719.386 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 913.869 M | 866.405 M | 954.866 M | 941.774 M | 905.435 M | 948.604 M | 1.477 B | |
| Total liabilities | 107.348 M | 91.207 M | 113.688 M | 111.335 M | 109.901 M | 120.075 M | 526.601 M | |
| Total current liabilities | 17.818 M | 18.565 M | 24.772 M | 37.112 M | 58.683 M | 64.734 M | 30.539 M | |
| Accounts Payable | 1.893 M | 1.793 M | 4.694 M | 5.233 M | 5.366 M | 8.584 M | 3.679 M | |
| Other liabilities | 35.859 M | 39.818 M | 40.004 M | 39.453 M | 21.839 M | 23.095 M | 27.896 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 445.493 M | |
| Other liabilities | 35.859 M | 39.818 M | 40.004 M | 39.453 M | 21.839 M | 23.095 M | 27.896 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 806.521 M | 775.198 M | 841.178 M | 830.439 M | 795.534 M | 828.529 M | 950.171 M | |
| Common stock | 218.276 M | 238.889 M | 309.360 M | 337.397 M | 340.564 M | 358.655 M | 362.634 M | |
| Retained earnings | 589.155 M | 537.244 M | 530.072 M | 498.984 M | 456.533 M | 461.380 M | 578.215 M |